{ "ok": true, "cik": "1566044", "ticker": "YARW", "name": "YARROW BIOSCIENCE, INC.", "filings": [ { "form": "8-K", "filed": "2026-09-14", "items": [ "1.01 Entry into a Material Definitive Agreement", "9.01 Financial Statements and Exhibits" ], "url": "https://www.sec.gov/Archives/edgar/data/1566044/000110465926107485/0001104659-26-107485-index.htm" }, { "form": "8-K", "filed": "2026-09-10", "items": [ "8.01 Other Events", "9.01 Financial Statements and Exhibits" ], "url": "https://www.sec.gov/Archives/edgar/data/1566044/000110465926106699/0001104659-26-106699-index.htm" }, { "form": "10-Q", "filed": "2026-08-13", "items": [], "url": "https://www.sec.gov/Archives/edgar/data/1566044/000156604426000010/0001566044-26-000010-index.htm" }, { "form": "8-K", "filed": "2026-07-30", "items": [ "8.01 Other Events" ], "url": "https://www.sec.gov/Archives/edgar/data/1566044/000110465926088662/0001104659-26-088662-index.htm" }, { "form": "8-K", "filed": "2026-07-28", "items": [ "1.01 Entry into a Material Definitive Agreement", "2.01 Completion of Acquisition or Disposition of Assets", "2.02 Results of Operations and Financial Condition", "3.02 Unregistered Sales of Equity Securities", "3.03 Material Modifications to Rights of Security Holders", "5.01 Changes in Control of Registrant", "5.02 Departure or Election of Directors; Appointment of Officers", "5.03 Amendments to Articles or Bylaws; Change in Fiscal Year", "5.05 Amendments to the Code of Ethics", "7.01 Regulation FD Disclosure", "9.01 Financial Statements and Exhibits" ], "url": "https://www.sec.gov/Archives/edgar/data/1566044/000110465926087601/0001104659-26-087601-index.htm" }, { "form": "8-K", "filed": "2026-07-21", "items": [ "7.01 Regulation FD Disclosure", "8.01 Other Events", "9.01 Financial Statements and Exhibits" ], "url": "https://www.sec.gov/Archives/edgar/data/1566044/000110465926085235/0001104659-26-085235-index.htm" } ], "events12m": 14, "sources": { "facts": "https://data.sec.gov/api/xbrl/companyfacts/CIK0001566044.json", "filings": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1566044" }, "license": "Figures as filed with the SEC. Card text CC BY 4.0, POPS4.", "notAdvice": "Reporting, not investment advice. No price targets, no buy or sell views.", "edgar": "🫧 Edgar looked up YARROW BIOSCIENCE, INC. ($YARW). Last filing: 8-K (1.01 Entry into a Material Definitive Agreement), 2026-09-14. 14 event filings (8-K) in the past twelve months.", "auditor": { "changes": [], "nonReliance": [], "restatedSince": null }, "metrics": { "fiscalYearEnd": "2025-12-31", "revenue": 570000, "revenueGrowth1y": 0.13772455089820368, "revenueGrowthPerYear": -0.115431858794388, "yearsOfData": 5, "operatingMargin": -52.19122807017544, "operatingMarginPrior": -87.0998003992016, "netMargin": -46.46140350877193, "operatingCashFlow": -33124000, "capitalSpending": null, "freeCashFlow": null, "researchAndDevelopment": 19237000, "researchShareOfRevenue": 33.74912280701754, "cash": 24027000, "longTermDebt": 0, "longTermDebtChange": null, "revenueHistory": [ { "fiscalYearEnd": "2021-12-31", "revenue": 931000 }, { "fiscalYearEnd": "2022-12-31", "revenue": 477000 }, { "fiscalYearEnd": "2023-12-31", "revenue": 424000 }, { "fiscalYearEnd": "2024-12-31", "revenue": 501000 }, { "fiscalYearEnd": "2025-12-31", "revenue": 570000 } ], "totalEquity": 27765000, "totalAssets": 30160000, "equityRatio": 0.9205901856763926, "returnOnEquity": -0.9538267603097424, "dividendsPaid": null, "payoutRatio": null, "dividendPerShare": null, "dividendYearsRising": null, "dividendCut": null, "priceBased": "Dividend yield, price/earnings and price/book need a share price. The boards carry filings only, so they are not shown.", "range80": { "low": 459924.35272406944, "high": 825845.9081888251, "baseline": 626685.3150620922, "n": 749, "band": "b00" }, "ifPaceHeld": { "low": 459924.35272406944, "high": 825845.9081888251 } }, "edgarette": "🔖 Exposure: revenue $570K (FY2025), total debt $0K. Experience: revenue up 13.8% on the year, down 11.5% a year over 4 years; operating margin -5219.1%, up from -8710.0%. Soundness: equity 92.1% of assets, return on equity -95.4%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $460K and $826K next year (method v3, set from 749 SEC company-years; on a year the method never saw, 83% landed inside). A range, not a forecast. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin -5219.1% against a -3.8% median; growth 13.8% against 13.7%.", "peers": { "sic": 2834, "sicDescription": "Pharmaceutical Preparations", "calendarYear": 2025, "minRevenue": 50000000, "depth": 4, "group": "2834", "growth": [ 0.1365, 111 ], "opMargin": [ -0.038, 114 ], "equityRatio": [ 0.4028, 118 ], "returnOnEquity": [ -0.0112, 100 ], "payoutRatio": [ 0.403, 13 ] }, "summary": "Yarrow Bioscience (YARW) grew revenue 13.8% in FY2025 to $1 million, operating margin -5219% against a -3.8% median for pharmaceutical preparations, equity 92.1% of assets. Every figure is from the company’s own annual report filed with the SEC.", "chart": "
YARROW BIOSCIENCE, INC. against its own record and its peers
Operating marginPeer median -3.8%-5219.1%Revenue, on the yearPeer median 13.7%13.8%Equity of assetsPeer median 40.3%92.1%Return on equityPeer median -1.1%-95.4%Gold tick: the median of 100–118 peers with $50M+ revenue in pharmaceutical preparations
", "chartHorizon": null, "backtest": { "tests": 6, "hits": 2, "rate": 0.3333333333333333, "method": "v3", "note": "hindsight: past years, same calibrated range. The range was calibrated on 2022-2024 SEC data, so years in that window are partly in-sample." }, "registry": { "logged": "2026-09-20T15:21:26.641Z", "hash": "da8a8b80a794d9c6", "status": "open" }, "caution": "Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.", "schema": "pops4.edgarette.card/1", "card": { "summary": "Yarrow Bioscience (YARW) grew revenue 13.8% in FY2025 to $1 million, operating margin -5219% against a -3.8% median for pharmaceutical preparations, equity 92.1% of assets. Every figure is from the company’s own annual report filed with the SEC.", "exposure": { "fiscalYearEnd": "2025-12-31", "revenue": 570000, "totalDebt": 0, "cash": 24027000 }, "experience": { "revenueGrowth1y": 0.13772455089820368, "revenueGrowthPerYear": -0.115431858794388, "operatingMargin": -52.19122807017544, "operatingMarginPrior": -87.0998003992016, "netMargin": -46.46140350877193, "freeCashFlow": null }, "soundness": { "equityRatio": 0.9205901856763926, "returnOnEquity": -0.9538267603097424, "payoutRatio": null, "dividendPerShare": null, "dividendYearsRising": null, "dividendCut": null, "note": "Dividend yield, price/earnings and price/book need a share price. The boards carry filings only, so they are not shown." }, "peers": { "sic": 2834, "sicDescription": "Pharmaceutical Preparations", "calendarYear": 2025, "minRevenue": 50000000, "depth": 4, "group": "2834", "growth": [ 0.1365, 111 ], "opMargin": [ -0.038, 114 ], "equityRatio": [ 0.4028, 118 ], "returnOnEquity": [ -0.0112, 100 ], "payoutRatio": [ 0.403, 13 ] }, "credibility": { "auditedYears": 5, "weight": "reasonable", "standard": "ASOP No. 25", "nonReliance": null, "auditorChange": null }, "range": { "low": 459924.35272406944, "high": 825845.9081888251, "baseline": 626685.3150620922, "coverage": 0.8, "method": "v3", "basis": "next fiscal year revenue: baseline = revenue x (1 + mean of one-year and three-year pace); range = 10th to 90th percentile of how SEC company-years of the same size band actually turned out", "calibratedOn": { "companyYears": 749, "sizeBand": "b00" }, "kind": "a calibrated range, not a forecast; no view on the share price", "track": { "backtest": { "tests": 6, "hits": 2, "rate": 0.3333333333333333, "method": "v3", "note": "hindsight: past years, same calibrated range. The range was calibrated on 2022-2024 SEC data, so years in that window are partly in-sample." }, "registry": { "logged": "2026-09-20T15:21:26.641Z", "hash": "da8a8b80a794d9c6", "status": "open" }, "scorecard": "https://www.pops4.com/boards/scorecard" } }, "caution": "Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.", "sources": { "facts": "https://data.sec.gov/api/xbrl/companyfacts/CIK0001566044.json", "filings": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1566044" } }, "definitions": { "operatingMargin": "Operating income divided by revenue.", "netMargin": "Net income divided by revenue.", "freeCashFlow": "Cash from operations minus spending on property and equipment.", "researchShareOfRevenue": "Research and development expense for the year as a share of revenue, both as filed.", "equityRatio": "Shareholders equity as a share of total assets, both as filed. Higher means less of the company is owed to someone else.", "returnOnEquity": "Net income for the year against shareholders equity at year end.", "payoutRatio": "Dividends paid as a share of net income, in the year the cash went out.", "dividendYearsRising": "Consecutive years, counted back from the last on record, in which dividend per share rose. A fall ends the run and is reported as dividendCut.", "revenueGrowthPerYear": "Compound annual growth between the first and latest fiscal years shown.", "credibility": "How much weight a record deserves, in the actuarial sense (ASOP No. 25): more audited years, more weight.", "peers": "Medians of SEC filers with $50M+ revenue in the same industry code (SIC), narrowest group with at least 8 filers, calendar-year figures from SEC XBRL frames.", "backtest": "The same if-the-pace-held arithmetic applied to the company's own past years, scored against what it actually reported next. Hindsight, and labelled so." } }